A double-blind, randomized phase III trial sponsored by the National Cancer Institute is investigating whether adding bevacizumab to standard adjuvant doxorubicin/cyclophosphamide followed by paclitaxel improves outcomes in lymph node-positive or high-risk lymph node-negative breast adenocarcinoma. The trial is currently active but no longer enrolling participants.
This NCI-sponsored, double-blind phase III trial (NCT00433511) is examining the clinical benefit of incorporating bevacizumab—an anti-VEGF monoclonal antibody—into a sequential adjuvant chemotherapy backbone of doxorubicin hydrochloride plus cyclophosphamide (AC) followed by paclitaxel in women with breast adenocarcinoma. Eligible populations include those with lymph node-positive disease or lymph node-negative disease carrying high-risk features for recurrence.
The rationale for adding bevacizumab centers on its anti-angiogenic mechanism: by neutralizing vascular endothelial growth factor (VEGF), bevacizumab may impair tumor neovascularization and limit residual micrometastatic disease following surgical resection. The AC-paclitaxel backbone itself targets tumor cell proliferation and division through distinct cytotoxic mechanisms, and post-operative administration is intended to eradicate residual disease and reduce recurrence risk.
The trial incorporates laboratory biomarker analysis and quality-of-life assessments as secondary endpoints, which may yield translational insights into predictive markers for bevacizumab response in the adjuvant breast cancer setting. The study is classified as active but not recruiting, indicating that follow-up and data collection are ongoing. Whether the addition of bevacizumab confers a meaningful efficacy advantage over chemotherapy alone in this population remains the central unanswered question of this investigation.
Key points
- Randomized, double-blind phase III design comparing AC followed by paclitaxel with or without bevacizumab in the adjuvant breast cancer setting
- Target population: lymph node-positive breast adenocarcinoma or high-risk lymph node-negative breast adenocarcinoma
- Bevacizumab's proposed benefit is anti-angiogenic: VEGF blockade to suppress residual tumor vascularity post-resection
- Trial includes biomarker and quality-of-life endpoints alongside primary efficacy outcomes
- Currently active but no longer enrolling; final results are pending
Why it matters
Defining the role of bevacizumab in adjuvant breast cancer chemotherapy regimens remains clinically unresolved; results from this trial could inform risk-stratified treatment decisions for high-risk early-stage breast adenocarcinoma. Biomarker sub-analyses may help identify subpopulations most likely to derive benefit from anti-VEGF therapy in this context.